Access
To read this story in full you will need to login or make a payment (see right).
Brief Communication Arising
Nature 445, E19 (22 February 2007) | doi:10.1038/nature05657; Published online 21 February 2007
Open Innovation Challenges
-
Fast Growth of Transformed Soybean Shoots
A method for accelerating growth of soybean shoots is desired.
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
- More Challenges
- Powered by:
nature jobs
Assistant Professor in Pharmacology
- St. George University
- Grenada, West Indies
Biochemist (Genetics / dna) Needed For Growing Nanostructure Designing Co. In Philadelphia
- KSR
- Blue Bell, PA, USA
Bone Metastasis: Can osteoclasts be excluded?
T. John Martin1 & Gregory R. Mundy2
Abstract
Arising from: D. H. Jones et al. Nature 440, 692–696 (2006); Jones et al. reply
The RANK/RANKL signalling mechanism is the final common pathway of osteoclast formation and activity1. Inhibitors of RANK ligand (RANKL) that bind to RANK (for 'receptor activator of NF-
B'), such as osteoprotegerin (OPG), neutralizing antibodies against RANKL and soluble RANK antagonists, are well described inhibitors of bone metastasis in preclinical and clinical models, presumably because of their effects on osteoclasts2. Jones et al.3 show that OPG inhibits bone metastasis after intracardiac injection of B16F10 murine melanoma cells, but claim that bone metastases are entirely independent of osteoclast formation and bone resorption: rather, they are caused by an effect on cell migration through RANK. However, we question whether these surprising conclusions are rigorously supported by their data3.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Bone-breaking cancer treatmentNature Medicine News and Views (01 Jan 2007)
Bone-breaking cancer treatmentNature Medicine News and Views (01 Jan 2007)
